Systematic Review of Probiotics for Cystic Fibrosis Patients: Moving Forward

Imagem de Miniatura
Arquivos
art_NERI_Systematic_Review_of_Probiotics_for_Cystic_Fibrosis_Patients_2019.PDF (464.85 KB)
Citações na Scopus
22
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
TAMINATO, Monica
Citação
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, v.68, n.3, p.394-399, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Cystic fibrosis (CF) is associated with chronic respiratory disease and pancreatic insufficiency and results in the malabsorption of nutrients and intestinal inflammation. There is evidence that probiotic supplementation may impact the gastrointestinal and respiratory microbiota. This study aimed to categorize current evidence regarding the effects of supplementing with probiotics in CF patients on gastrointestinal and respiratory outcomes according to the type of intervention. Methods: The initial database search included all identified studies according to the recommendations of the Cochrane Collaboration, regardless of language, publication date or design. Studies were categorized by probiotic strain (Lactobacillus reuteri; Lactobacillus rhamnosus GG or a mix of strains); dosage (low dosage if <10(9) CFU [ colony forming units] or high dosage if >10(9) CFU); and duration of intervention (1, 3, 6, or 12 months). Assessment of quality was performed based on the Cochrane risk of bias criteria and the Downs & Black checklist. Results: A total of 205 studies were identified; however, only 9 met the criteria for inclusion. The studies were considered to have a high risk of bias, hampering the possibility of performing a meta-analysis. Eighty percent of the studies (4 of 5) reported a positive result for intestinal inflammation, and another 4 studies (4 of 5) reported a positive result for pulmonary exacerbation frequency, regardless of the treatment approach. Conclusions: The present data indicate a promising future for probiotic use in cystic fibrosis, which has an impact on exacerbations and intestinal inflammation; however, further studies of standardized therapeutic interventions are required.
Palavras-chave
cystic fibrosis, intestinal inflammation, probiotics, pulmonary exacerbation
URI
https://observatorio.fm.usp.br/handle/OPI/31942
Referências
  1. Alexandre Y, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-107
  2. Ananthan A, 2016, EUR J PEDIATR, V175, P1255, DOI 10.1007/s00431-016-2769-8
  3. Anderson JL, 2017, J CYST FIBROS, V16, P186, DOI 10.1016/j.jcf.2016.09.004
  4. Blanco PG, 2004, AM J PHYSIOL-GASTR L, V287, pG491, DOI 10.1152/ajpgi.00452.2003
  5. Britto MT, 2002, CHEST, V121, P64, DOI 10.1378/chest.121.1.64
  6. Bruzzese E, 2004, ALIMENT PHARM THER, V20, P813, DOI 10.1111/j.1365-2036.2004.02174.x
  7. Bruzzese E, 2007, CLIN NUTR, V26, P322, DOI 10.1016/j.clnu.2007.01.004
  8. Bruzzese E, 2018, J CYST FIBROS, V17, P375, DOI 10.1016/j.jcf.2017.10.014
  9. Bruzzese E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087796
  10. Cotar Ani Ioana, 2010, Roum Arch Microbiol Immunol, V69, P213
  11. de Freitas MB, 2018, EUR J CLIN NUTR, V72, P736, DOI 10.1038/s41430-017-0043-4
  12. del Campo R, 2014, J CYST FIBROS, V13, P716, DOI 10.1016/j.jcf.2014.02.007
  13. Di Nardo G, 2014, J PEDIATR GASTR NUTR, V58, P81, DOI 10.1097/MPG.0000000000000187
  14. Dorsey Jill, 2017, J Cyst Fibros, V16 Suppl 2, pS14, DOI 10.1016/j.jcf.2017.07.014
  15. Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
  16. Fallahi G, 2013, TURKISH J PEDIATR, V55, P475
  17. FAO/WHO, 2002, GUID EV PROB FOOD
  18. GIBSON GR, 1995, J NUTR, V125, P1401, DOI 10.1093/jn/125.6.1401
  19. Higgins J, 2005, COCHRANE HDB SYSTEMA
  20. Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
  21. Hoen AG, 2015, J PEDIATR-US, V167, P138, DOI 10.1016/j.jpeds.2015.02.049
  22. Infante Pina D, 2008, An Pediatr (Barc), V69, P501
  23. Jafari SA, 2013, IRAN J PEDIATR, V23, P669
  24. Lin L, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-016-0187-3
  25. Liou TG, 2001, AM J EPIDEMIOL, V153, P345, DOI 10.1093/aje/153.4.345
  26. Morais Mauro Batista de, 2006, J. Pediatr. (Rio J.), V82, pS189, DOI 10.1590/S0021-75572006000700009
  27. Nikniaz Z, 2017, WORLD J PEDIATR, V13, P307, DOI 10.1007/s12519-017-0033-6
  28. Putignani L, 2014, PEDIATR RES, V76, P2, DOI 10.1038/pr.2014.49
  29. Ralhan A, 2016, J INNATE IMMUN, V8, P531, DOI 10.1159/000446840
  30. Rogers GB, 2016, PEDIATR PULM, V51, pS35, DOI 10.1002/ppul.23544
  31. Rubin JL, 2017, CURR MED RES OPIN, V33, P667, DOI 10.1080/03007995.2016.1277196
  32. Van Biervliet S, 2017, CLIN NUTR ESPEN, V18, P37, DOI 10.1016/j.clnesp.2017.01.007
  33. Weiss B, 2010, PEDIATR PULM, V45, P536, DOI 10.1002/ppul.21138

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/36
Artigos e Materiais de Revistas Científicas - ODS/03